Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has successfully registered its IPO on the Sci-Tech Innovation Board, marking a significant milestone for the company in its growth trajectory [1] Company Overview - Established in 2009, Baiaosaitu is a preclinical CRO and biotechnology company [1] - The company offers various innovative animal models and preclinical pharmaceutical research and development services based on its proprietary gene editing technology [1] Technology and Services - Baiaosaitu utilizes its self-developed RenMice fully human antibody mouse platform, which includes multiple series such as RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic [1] - The platform targets nearly a thousand potential drug targets in the human body for large-scale drug discovery and development [1] - The company has plans to transfer, license, or co-develop promising antibody molecules [1] IPO Journey - The IPO application for Baiaosaitu was accepted on June 20, 2023, and the company passed the review on September 24, 2023 [1] - The registration for the IPO was submitted on September 26, 2023 [1]

Group 1 - This week, four companies successfully passed the IPO review, aiming to raise a total of 12.233 billion yuan [1] - Among the approved IPOs, the company "Mole Thread" achieved the fastest review time of 88 days since the beginning of 2024 [2] - The company "Bai'ao Saitu" also submitted its registration on the same day it passed the review [2] Group 2 - Two companies were approved for refinancing this week, with a total fundraising target of 824 million yuan [1] - "Pulan Software" and "Maolai Optics" are the two companies that received approval for refinancing [1][2] Group 3 - "Bai'ao Saitu" focuses on preclinical CRO and biotechnology services, utilizing its self-developed gene editing technology [3] - The company plans to invest 45.358 million yuan in early drug development services, which constitutes 38.28% of its total fundraising [5] - The company reported a net profit of 33.54 million yuan for the last year, marking a significant turnaround from previous losses [4] Group 4 - "Hengdongguang" specializes in the research, manufacturing, and sales of passive optical devices in the optical communication field [7] - The company aims to raise 493.6329 million yuan through its IPO, with a focus on expanding its product offerings [8] - The company reported a net profit of 142.79 million yuan for the first half of 2025, reflecting a strong growth trajectory [9] Group 5 - "Mole Thread" is engaged in the research, design, and sales of GPUs and related products, having launched four generations of GPU architecture [14] - The company plans to raise 800 million yuan, with a significant portion allocated to AI chip development [18] - The company reported a net loss of 27.094 million yuan for the first half of 2025, indicating ongoing challenges despite its innovative product offerings [17] Group 6 - "Nanwang Digital" provides comprehensive digital construction solutions for the power energy sector, focusing on digital transformation [21] - The company aims to raise between 300 million and 476 million yuan through its IPO [22] - The company reported a net profit of 15.47 million yuan for the first half of 2025, showing a positive trend in profitability [23]

Core Viewpoint - The initial public offering (IPO) application of Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. has been approved by the Shanghai Stock Exchange's listing committee, aiming to raise 1.185 billion yuan through the issuance of approximately 99.85 million shares [1] Financial Performance - The company reported revenues of 534 million yuan, 717 million yuan, and 980 million yuan for the years 2022, 2023, and 2024 respectively, indicating a revenue growth of 36.76% in 2024 [1] - The net profit figures for the same years were -600 million yuan, -382 million yuan, and 33.54 million yuan, showing a significant turnaround with a year-on-year growth of 108.76% in net profit for 2024 [1] Research and Development - The company's R&D expenditures over the past three years were 699 million yuan, 474 million yuan, and 324 million yuan, representing 130.96%, 66.17%, and 33.04% of revenue respectively [1] - As of December 31, 2024, the company employed 337 R&D personnel, accounting for 30.78% of its total workforce [1] Use of Proceeds - The funds raised from the IPO will be allocated to the construction of a drug early-stage R&D service platform, antibody drug R&D and evaluation projects, clinical and preclinical R&D projects, and to supplement working capital [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is preparing for its IPO on the Sci-Tech Innovation Board, facing challenges such as high debt, reduced fundraising, and declining R&D expenses while showing revenue growth and a return to profitability [1][16]. Group 1: Company Overview - Baiaosaitu is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on self-developed gene editing technology [1]. - The company has established partnerships with the top ten global pharmaceutical companies based on projected sales revenue for 2024 [1]. Group 2: Ownership and Control - The actual controller's voting rights are below 30%, with significant outstanding loans [5]. - The controlling shareholders, Shen Yuelai and Ni Jian, hold a combined voting power of 27.03% [4][5]. - Shen Yuelai and Ni Jian have substantial repayment obligations totaling approximately 113.4 million yuan by 2025 [5][6]. Group 3: Financial Performance - Baiaosaitu's revenue has steadily increased from 534 million yuan in 2022 to 980 million yuan in 2024, with year-on-year growth rates of 50.58%, 34.28%, and 36.76% respectively [16]. - The company achieved a net profit of 34 million yuan in 2024, marking a turnaround from previous losses [16]. - The asset-liability ratio stands at 65.28%, significantly higher than industry peers, indicating liquidity pressure [16][17]. Group 4: Fundraising and Investment Plans - The company plans to raise 1.185 billion yuan through its IPO, with a significant reduction of over 700 million yuan from the initial fundraising target [7][8]. - The funds will be allocated to early drug development service platform construction, antibody drug research, preclinical research, and working capital [7][8]. Group 5: R&D and Personnel - R&D expenses have decreased significantly over the past three years, from 699 million yuan in 2022 to 324 million yuan in 2024, with a corresponding drop in R&D personnel from 627 to 337 [11][13]. - The R&D expense ratio for 2024 is projected at 33.04%, which is below the industry average [12]. Group 6: Legal and Patent Issues - The company is facing a lawsuit for patent infringement, with a claim for 1 million yuan in damages [15]. - Baiaosaitu holds 192 patents, with core technologies including ESC/HR and CRISPR/EGE, which are based on licensed foreign technologies [15].

Summary of Key Points Core Viewpoint - This week, one new stock will be available for subscription, while four companies are undergoing IPO reviews, indicating ongoing activity in the capital markets [2][3]. Group 1: New Stock Subscription - One new stock, Aomeisen, will be available for subscription on Monday, September 25 [2]. - Last week, Shichang Co. debuted on the North Exchange, experiencing a significant first-day increase of 271.56% [2]. Group 2: Company Performance and Financials - Shichang Co. specializes in the research, production, and sales of automotive fuel systems, primarily selling to major vehicle manufacturers like Geely and FAW [2]. - Baiaosaitu, known as the "first stock in gene editing," plans to raise approximately 11.85 billion yuan for early drug development services and other projects [3][5]. - Baiaosaitu's projected revenues for 2022, 2023, and 2024 are 534 million yuan, 717 million yuan, and 980 million yuan, respectively, with net profits expected to improve from a loss of 602 million yuan in 2022 to a profit of 33.54 million yuan in 2024 [3][4]. Group 3: Fundraising and Investment Plans - The fundraising plan for Baiaosaitu includes allocations of 45.36 million yuan for early drug development services, 31.65 million yuan for antibody drug research, and 16.5 million yuan for preclinical research [6]. - The total investment amount for these projects is 118.5 million yuan, with the majority directed towards early drug development services [6].

Summary of Key Points Core Viewpoint - Four companies are set to present their IPO applications at the upcoming listing committee meetings of the Shenzhen Stock Exchange, Shanghai Stock Exchange, and Beijing Stock Exchange, indicating a robust pipeline of new listings in the market [1]. Group 1: Upcoming IPOs - Yuan Chuang Co., Ltd. plans to list on the Shenzhen Main Board, focusing on the research, production, and sales of rubber track products [3]. - Xin Guang Yi intends to list on the ChiNext Board, specializing in high-performance special functional materials, including anti-adhesion special films and strong resistance special films [4]. - You Xun Co., Ltd. and Bai Ao Sai Tu are both targeting the Sci-Tech Innovation Board (STAR Market) for their IPOs, with You Xun focusing on optical communication front-end transceiver chips and Bai Ao Sai Tu providing innovative model animals and preclinical pharmaceutical research services based on self-developed gene editing technology [5]. Group 2: Fundraising Details - Bai Ao Sai Tu is expected to raise the highest amount of 1.185 billion yuan, with funds allocated for early drug research service platform construction, working capital, and various R&D projects [1]. - You Xun plans to raise 808 million yuan, while Xin Guang Yi aims for 638 million yuan in their respective fundraising efforts [1]. - The geographical distribution of the upcoming IPOs includes one company each from Beijing, Fujian, Jiangsu, and Zhejiang provinces [1]. Group 3: Underwriting Institutions - You Xun and Xin Guang Yi are both backed by CITIC Securities as their underwriting institution [2]. - Bai Ao Sai Tu is sponsored by China International Capital Corporation (CICC), while Yuan Chuang is underwritten by Guotai Junan Securities [5].